HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life-Reference-Cited by-同舟云学术

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life

Published:2013-01-09 Issue:4 Volume:6 Page:692-703
ISSN:1933-0219
Container-title:Mucosal Immunology
language:en
Short-container-title:Mucosal Immunol

Author:

Yates N L,Stacey A R,Nolen T L,Vandergrift N A,Moody M A,Montefiori D C,Weinhold K J,Blattner W A,Borrow P,Shattock R,Cohen M S,Haynes B F,Tomaras G D

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/mi2012107.pdf

Reference69 articles.

1. Cerutti, A. The regulation of IgA class switching. Nat Rev Immunol 8, 421–434 (2008).

2. Haase, A. Protection from HIV: Targeted Intervention Strategies, Whistler Conference Centre: British Columbia, (2011).

3. Bomsel, M. et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34, 269–280 (2011).

4. Tomaras, G.D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82, 12449–12463 (2008).

5. Moir, S. & Fauci, A.S. B cells in HIV infection and disease. Nat Rev Immunol 9, 235–245 (2009).

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages;Proceedings of the National Academy of Sciences;2024-01-09

2. Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans;AIDS Research and Human Retroviruses;2023-07-01

3. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial;Nature Medicine;2022-05-12

4. Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges;Frontiers in Immunology;2022-02-22

5. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial;Nature Medicine;2021-10